Pfizer wins right to challenge Prempro damages award; Asthma market flat until 2020 on Singulair rivals;

@FiercePharma: New issues at Ben Venue-J&J's CMO on Doxil-highlight pitfalls of contract manufacturing, WSJ reports. Piece | Follow @FiercePharma

> The Pennsylvania Supreme Court will review Pfizer's ($PFE) challenge to an $8.6 million punitive damages award in a Prempro case. News

> Takeda Pharmaceutical won European approval for its blood pressure drug Edarbi, saying that trials show its superiority to the highest doses of Daiichi Sankyo's Benicar and Novartis' Diovan. Item

> The asthma drug market will remain flat at around $14.4 billion through 2020, thanks in part to generic rivals for Merck's ($MRK) Singulair, Decision Resources concludes. Release

> Teva Pharmaceutical Industries ($TEVA) won an appeals court's backing for its Fentora patent, shutting out a Watson Pharmaceuticals ($WPI) copy until 2019. Story

> Watson Pharmaceuticals ($WPI) is plotting a 2012 launch for partner Antares Pharma's ($AIS) new treatment for overactive bladder, in a gel form. Article

> Amgen ($AMGN) will buy back about 83.3 million shares at $60 each, or 9.5% of its outstanding stock, as part of a $10 billion repurchase program. Report

> Women using antidepressants for premenstrual syndrome are more likely to get relief if they have multiple physical and psychological symptoms, rather than physical problems alone. More

> Depressive symptoms and impaired physical function tend to persist for long periods after an acute lung injury, a Johns Hopkins study found. Piece

Biotech News

@FierceBiotech: Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Story | Follow @FierceBiotech

 @RyanMFierce: Some upbeat Ph2 data in breast cancer from Puma Biotech, which licensed the drug from Pfizer in October. Release  | Follow @RyanMFierce

@MaureenFierce: Reading: The loss of the middle (drugs and the people who find them). Story by @Dereklowe | Follow @MaureenFierce

 @MarkHFierce: But is the FDA bill an overall improvement? Curious what people think. | Follow @MarkHFierce

@FierceMedDev: Recently profiled them: Bluegrass Vascular starts 1st clinical study of the Surfacer inside-out access catheter system. Release | Follow @FierceMedDev

> Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Item

> J&J locks in blood cancer compound in $975M pact. Story

And Finally... Men using three or more medications have higher rates of erectile dysfunction, according to a study. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.